USA – Novavax seeks FDA emergency approval for COVID-19 vaccine by May

Novavax’s COVID-19 vaccine could receive an emergency use approval from the US Food and Drug Administration (FDA) in May, according to the company’s chief executive officer Stanley Erck.

Earlier this week, Erck told CNBC that the company’s discussions with the FDA are ongoing, but the hope is that the US regulatory agency will agree to review data from a UK-based trial of the COVID-19 vaccine.

In January, Novavax published results from the UK trial, which demonstrated a vaccine efficacy rate of 89.3%.

Preliminary analysis found that the UK COVID-19 variant was detected in over 50% of the PCR-test confirmed cases – with 32 cases being caused by the UK variant, 24 by the non-variant and six ‘unknown’…